Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and dexamethasone 40 mg orally on Days 1 through 4. Epcoritamab will be administered subcutaneously (SC) on Days 1, 8, and 15. Patients will receive granulocyte colony stimulating factor (G-CSF) between Day 8 through Day 10 of each cycle of combination therapy. Patients will then undergo radiology imaging for disease assessment. Patients may proceed to

Trial Details

NCT ID
NCT05852717
Phase
PHASE2
Sponsor
Dipenkumar Modi
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • AutoSCT OR CAR T-cell Therapy
  • GDP
  • Epcoritamab
Locations (sample)
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Dallas, Texas, United States|32.78306,-96.80667
  • Charlottesville, Virginia, United States|38.02931,-78.47668

Key Eligibility Criteria

  • Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be…
  • Age ≥ 18 years at the time of consent.
  • ECOG Performance Status of 0-2 within 28 days prior to registration.
  • Histologically confirmed CD20+ relapsed large cell lymphoma according to the 5th edition of the WHO classification of the hematolymphoid tumors and…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →